

## AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

March 19, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--Mar. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13745239.

This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at <a href="https://www.angiodynamics.com">www.angiodynamics.com</a>. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 10:00 a.m. ET on Thursday, April 4, 2024, until 11:59 p.m. ET on Thursday, April 11, 2024. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13745239.

## About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life.

The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit <a href="https://www.angiodynamics.com">www.angiodynamics.com</a>.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240319173188/en/

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408

Source: AngioDynamics, Inc.